Your browser is no longer supported. Please, upgrade your browser.
Settings
APLT Applied Therapeutics, Inc. daily Stock Chart
APLT [NASD]
Applied Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.69 Insider Own23.70% Shs Outstand19.09M Perf Week-6.89%
Market Cap286.16M Forward P/E- EPS next Y-2.45 Insider Trans0.00% Shs Float10.84M Perf Month44.27%
Income- PEG- EPS next Q-0.49 Inst Own37.80% Short Float0.55% Perf Quarter68.43%
Sales- P/S- EPS this Y-285.80% Inst Trans2.27% Short Ratio2.67 Perf Half Y53.74%
Book/sh2.87 P/B5.22 EPS next Y0.40% ROA- Target Price24.33 Perf Year-
Cash/sh2.15 P/C6.96 EPS next 5Y- ROE- 52W Range7.95 - 20.50 Perf YTD59.47%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-26.88% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low88.55% ATR1.52
Employees9 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)53.29 Volatility12.14% 11.98%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.90 Prev Close15.30
ShortableYes LT Debt/Eq0.00 EarningsNov 11 Payout- Avg Volume22.51K Price14.99
Recom1.50 SMA20-3.90% SMA5021.42% SMA20042.78% Volume20,256 Change-2.03%
Jun-10-19Initiated Robert W. Baird Outperform $24
Jun-10-19Initiated Cowen Outperform
Jun-10-19Initiated Citigroup Buy $29
Nov-13-19 07:00AM  Applied Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-12-19 07:00AM  Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock GlobeNewswire
Oct-16-19 07:00AM  Applied Therapeutics to Present Data Highlighting AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2019 Annual Meeting GlobeNewswire +5.87%
Oct-14-19 06:35AM  Did Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Buy Up More Shares? Simply Wall St.
Sep-17-19 07:00AM  Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) GlobeNewswire
Sep-13-19 07:00AM  Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting GlobeNewswire
Sep-11-19 12:42PM  Top Ranked Momentum Stocks to Buy for September 11th Zacks
Sep-09-19 08:01AM  Top Ranked Momentum Stocks to Buy for September 9th Zacks
Sep-04-19 07:00AM  Applied Therapeutics Announces Initiation of Phase 3 Registrational Trial of AT-001 in Diabetic Cardiomyopathy (ARISE-HF) GlobeNewswire
Sep-03-19 10:45AM  Applied Therapeutics, Inc. (APLT) Shares March Higher, Can It Continue? Zacks -9.26%
Aug-28-19 07:00AM  Applied Therapeutics to Present at Bairds 2019 Global Healthcare Conference GlobeNewswire
Aug-14-19 03:51PM  What Percentage Of Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Do Insiders Own? Simply Wall St. -5.66%
Aug-12-19 07:00AM  Applied Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire +5.94%
Aug-08-19 07:00AM  Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study GlobeNewswire -8.11%
Jun-24-19 07:00AM  Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia GlobeNewswire
Jun-21-19 07:00AM  Applied Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire -6.59%
Jun-10-19 10:05AM  Applied Therapeutics Stock Jumps as Analysts Give It a Bullish Welcome Barrons.com +6.45%
Jun-07-19 07:30AM  Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions GlobeNewswire
May-28-19 07:30AM  Applied Therapeutics Announces FDA Orphan Drug Designation for AT-007 in Galactosemia GlobeNewswire
May-24-19 07:00AM  Applied Therapeutics to Present Data at ESC-HF Highlighting AT-001, a Novel, Potent and Selective Aldose Reductase Inhibitor for Treatment of Diabetic Cardiomyopathy GlobeNewswire
May-20-19 10:15PM  Applied Therapeutics Inc (APLT) President and CEO Shoshana Shendelman Bought $1.3 million of Shares GuruFocus.com
May-08-19 07:11AM  Uber in drivers seat as IPO market gears up for busiest week since 2015 MarketWatch
May-07-19 10:46AM  The Applied Therapeutics IPO: What You Need To Know Benzinga
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.